ANCA-associated vasculitis samples are incredibly important for research into the mechanisms, biomarkers, disease progression, immune responses, and treatment of antineutrophil cytoplasmic antibody-associated vasculitis.

Worldwide annual incidence of AAV is generally reported at 1.2 to 2.0 cases per 100,000 individuals, with a prevalence of 4.6 to 18.4 cases per 100,000 individuals.

At Bay Biosciences, we provide high-quality ANCA-associated vasculitis biospecimens, including serum, plasma, PBMCs, and other relevant human samples.

Understanding ANCA-Associated Vasculitis

ANCA-associated vasculitis (AAV) comprises a group of rare autoimmune disorders that cause inflammation and damage in small blood vessels.

The three major clinical forms include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

These disorders can affect several organs, including the kidneys, lungs, upper respiratory tract, skin, nerves, and cardiovascular system.

The disease gets its name from anti-neutrophil cytoplasmic antibodies (ANCAs), the autoantibodies that drive it. These antibodies target two enzymes found inside neutrophils: proteinase 3 (PR3) and myeloperoxidase (MPO).

Under normal conditions, these enzymes stay contained inside the neutrophil. But certain triggers, such as infection, can prime neutrophils and cause PR3 and MPO to move to the cell surface.

Once exposed, ANCAs bind to them. This binding activates the neutrophils fully. Activated neutrophils release reactive oxygen species and enzymes that break down tissue, and they also form neutrophil extracellular traps (NETs). This activity happens directly against the walls of small blood vessels.

The result is damage to the endothelial cells lining the vessels, along with necrotizing inflammation .

Over time, this weakens vessel walls and impairs blood flow to the organs those vessels supply, which is why AAV can present across so many different organ systems.

ANCA-Associated Vasculitis Samples for Research

Symptoms of ANCA-Associated Vasculitis

Symptoms vary according to the type of AAV and the organs affected.

Patients may initially experience general inflammatory symptoms such as fatigue, fever, reduced appetite, weight loss, and joint or muscle pain

Respiratory involvement may cause persistent coughing, shortness of breath, chest discomfort, or coughing up blood.

Upper respiratory tract involvement can produce nasal congestion, sinus problems, nosebleeds, or other ear, nose, and throat symptoms.

Similarly, skin involvement may result in rashes or purplish discoloration, while nerve involvement can cause numbness, tingling, weakness, or peripheral neuropathy.

Kidney involvement can produce blood or protein in the urine, changes in kidney function, swelling, or high blood pressure.

Some patients may develop severe organ complications when inflammation remains uncontrolled.

Researchers therefore examine blood, serum, plasma, urine, and other biological materials to investigate molecular changes associated with different manifestations of AAV.

Causes and Risk Factors of ANCA-Associated Vasculitis

The exact cause of ANCA-associated vasculitis remains unclear.

Researchers believe that genetic susceptibility, immune dysregulation, environmental influences, and other triggers may contribute to disease development.

1. Immune Dysregulation

Abnormal immune activity plays a central role in AAV. The immune system produces autoantibodies that interact with neutrophil-associated proteins and contribute to inflammatory blood vessel injury.

2. Genetic Susceptibility

Genetic factors may influence susceptibility to different forms of AAV. Researchers have identified associations between genetic variation and disease subtype, ANCA specificity, and clinical characteristics.

3. Age and Gender

AAV most commonly appears in people between 40 and 50 years old, and men carry a somewhat greater risk of developing the condition.

4. ANCA Specificity

PR3-ANCA and MPO-ANCA show different associations with AAV subtypes. PR3-ANCA occurs more frequently in GPA, whereas MPO-ANCA occurs more often in MPA.

Diagnosis of ANCA-Associated Vasculitis

Healthcare professionals generally begin the evaluation with a detailed medical history and physical examination.

They assess symptoms, organ involvement, previous medical conditions, medication exposure, and other factors that may help distinguish AAV from conditions with similar clinical presentations.

Similarly, laboratory testing plays an important role in the diagnostic process.

Clinicians may evaluate inflammatory markers, kidney function, blood counts, urinalysis, and ANCA levels.

Laboratory assays can identify PR3-ANCA and MPO-ANCA, while additional testing can help exclude other diseases that may produce similar findings.

Researchers also study these antibodies as potential biomarkers for disease characterization and monitoring.

Moreover, imaging techniques can help evaluate affected organs.

Depending on the clinical presentation, healthcare professionals may use chest radiography, computed tomography, magnetic resonance imaging, or other imaging procedures.

A tissue biopsy may also provide important histological information and help confirm vasculitis when clinicians consider it appropriate.

Researchers use Vasculitis Blood Samples, including serum and plasma, to investigate circulating antibodies, inflammatory mediators, immune-cell activity, and other molecular features associated with AAV.

Treatment of ANCA-Associated Vasculitis

Treatment aims to control inflammation, achieve remission, prevent organ damage, and reduce the risk of relapse.

Clinicians select treatment according to disease severity, affected organs, disease subtype, previous treatment, and other patient-specific factors.

Current guidelines include immunosuppressive approaches and glucocorticoid-sparing strategies for appropriate patients.

For severe GPA and MPA, clinicians may use therapies such as rituximab or cyclophosphamide together with glucocorticoid-based treatment.

However, it is important to highlight that treatment approaches for EGPA can differ according to disease manifestations and severity.

Applications of ANCA-Associated Vasculitis Samples for Research

ANCA-Associated Vasculitis Biospecimens

ANCA-Associated Vasculitis Biospecimens can support research into the cellular and molecular mechanisms involved in autoimmune vascular inflammation.

Vasculitis Blood Samples

Vasculitis Blood Samples provide researchers with access to circulating biological material for investigating autoantibodies, inflammatory proteins, immune-cell populations, and other disease-related factors. Researchers can also compare samples collected from different disease stages or clinical groups when appropriate patient information accompanies the specimens.

Human Blood Samples

Human Blood Samples can provide whole blood or blood-derived components for immunological and translational studies. Researchers may use these materials to isolate specific cellular populations, evaluate circulating biomarkers, or develop and validate laboratory assays.

Autoimmune Disease Samples

Since AAV belongs to the broader group of autoimmune diseases, Autoimmune Disease Samples can provide valuable comparative material for immunology and biomarker studies. Researchers may compare biological signatures across autoimmune conditions to investigate shared inflammatory pathways and disease-specific features.

Frequently Asked Questions

What does ANCA stand for?

ANCA stands for anti-neutrophil cytoplasmic antibodies. These are autoantibodies that target enzymes inside neutrophils, a type of white blood cell.

Why are serum and plasma useful for ANCA vasculitis research?

Serum and plasma allow researchers to study circulating antibodies, inflammatory proteins, complement factors, cytokines, and other biomarkers associated with AAV. Researchers can also use these samples for biomarker discovery and assay development.

Are ANCA-associated vasculitis biospecimens ethically sourced?

Yes. All of our human biospecimens are collected through appropriate consent and IRB-approved protocols.

Supporting Your Research with Bay Biosciences

At Bay Biosciences, we provide high-quality human biospecimens to support autoimmune disease research, biomarker discovery, translational studies, and drug development.

Our comprehensive range of biospecimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.